PRINCETON, NJ – (BUSINESS THREAD) – Bristol Myers Squibb (NYSE: BMY) announced today that the Biologics License Application (BLA) for lysocabtagogenic maraleucel (lyso-cell) for the treatment of adults with relapse or refractory (R / R) large B-cell lymphoma after at least two previous therapies are being reviewed by the US Food and Drug Administration (FDA) and the company has not received a decision on them. As previously announced, the FDA has not provided a new action date for this application. Bristol Myers Squibb is still working closely with the FDA to support the BLA’s ongoing review of lyso cell and is committed to bringing this therapy to patients.
As the FDA approval of liso-cell did not take place on December 31, 2020, none of the three required milestones for the payment of the Bristol Myers Squibb Contingent Value Right (CVR) (NYSE: BMY-RT) has been met not. As a result, on 1 January 2021, the Conditional Values Agreement (CVR Agreement) under which the CVRs were issued was automatically terminated in accordance with its terms and the CVRs are no longer eligible for payment under the CVR. agreement not. The CVRs will no longer trade on the NYSE.
For more information, refer to: https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Statement-on-Status-of-Liso-cel-Application-and-Contingent- Value -Rights / default.aspx or call EQ Shareowner Services at 1-833-503-4131.
Bristol Myers Squibb: Creating a Better Future for People with Cancer
Bristol Myers Squibb was inspired by a single vision – to transform people’s lives through science. The aim of the company’s cancer research is to deliver medicines that offer every patient a better, healthier life and to enable healing. Researchers at Bristol Myers Squibb, building on a legacy in a wide range of cancers that have changed the survival expectancy for many, are exploring new frontiers in personalized medicine and transforming data through innovative digital platforms into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from all angles. Cancer can have a relentless grip on many parts of a patient’s life, and Bristol Myers Squibb is committed to addressing all aspects of care, from diagnosis to survival. Because Bristol Myers Squibb as a leader in cancer care is empowering all people with cancer to have a better future.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company aiming to discover, develop and deliver innovative medicines that dominate patients as serious diseases. For more information on Bristol Myers Squibb, visit our BMS.com or follow us on LinkedIn,Twitter, YouTube, Facebook and Instagram.
Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. In some countries outside the US, Celgene and Juno Therapeutics are referred to as Celgene, a Bristol Myers Squibb company, and Juno Therapeutics, a Bristol Myers Squibb company, due to local laws.
Bristol Myers Squibb Warning Statement for Forward-Looking Statements
This press release contains ‘forward-looking statements’ within the meaning of the Private Securities Litigation Act of 1995 concerning, inter alia, the research, development and commercialization of pharmaceutical products. All statements that are not explanations of historical facts are or can be considered as forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections on our future financial results, objectives, plans and objectives, and involve inherent risks, assumptions and uncertainties, including internal or external factors that may delay, infer or alter any of them. in the next few years, which is difficult to predict, may be beyond our control and may cause our future financial results, objectives, plans and objectives to differ materially from those expressed or implied in the statements. These risks, assumptions, uncertainties and other factors include whether or not liso-cell will be approved by the FDA. No forward-looking statement can be guaranteed. Forward-looking statements in this press release must be evaluated together with the many risks and uncertainties affecting the business and market of Bristol Myers Squibb, particularly those discussed in the warning statement and risk factors in Bristol Myers Squibb’s annual report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only from the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to update or revise any forward-looking statement in public, whether due to new information, future events, changed circumstances or otherwise.
corporate financial news